International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

NLRP3 Inflammasome in Liver Diseases: From Molecular Pathogenesis to Emerging Therapeutic Strategies

Kunj R. Ghantiwala[1], Ruchik Kevadiya[2], Arpit R. Thakor[3], Milind S. Chapatwala[4], Urmi Parmar[5]

[1]Junior Resident, Otorhinolaryngology Department, GMERS Medical College, Navsari, Gujarat, India
[2]PGY3 Resident, Internal Medicine Department, Henry Ford Hospital Rochester/Wayne State University, Rochester Hills, Michigan, USA
[3]Medical Officer, Medicine Department, Larsen & Toubro Health and Dialysis, Surat, Gujarat, India
[4]Medical Officer, Medicine Department, Surat General Hospital, Surat, Gujarat, India

Abstract

Liver diseases represent a major global health burden, with chronic inflammation, immune dysregulation, and progressive fibrosis contributing to disease progression and complications. Recent advances in hepatology have highlighted the critical role of innate immune pathways in hepatic injury, particularly the NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome. As a central regulator of inflammatory responses, the NLRP3 inflammasome senses cellular stress signals, including reactive oxygen species, mitochondrial dysfunction, extracellular ATP, and pathogen-associated molecular patterns. Upon activation, it promotes caspase-1 activation and subsequent maturation of pro-inflammatory cytokines, including interleukin (IL)-1β and IL-18, leading to pyroptotic cell death and amplification of hepatic inflammation.

Emerging evidence demonstrates that dysregulated NLRP3 activation contributes to the pathogenesis of multiple liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), alcohol-associated liver disease, viral hepatitis, liver fibrosis, and hepatocellular carcinoma. In MASLD/MASH, metabolic stress, lipotoxicity, and oxidative injury activate NLRP3 signaling, promoting hepatocyte damage, macrophage activation, and hepatic stellate cell-mediated fibrosis. Similarly, alcohol-induced gut-derived endotoxemia and oxidative stress stimulate NLRP3 activation, contributing to inflammatory liver injury.

Given its central role in hepatic inflammation and fibrosis, the NLRP3 inflammasome has emerged as a promising therapeutic target. Experimental studies investigating direct NLRP3 inhibitors, IL-1 pathway blockade, caspase-1 inhibition, metabolic therapies, and lifestyle interventions suggest potential benefits in reducing liver inflammation and disease progression. However, challenges remain regarding clinical translation, long-term safety, and selective modulation of immune responses.

This review summarizes the molecular mechanisms underlying NLRP3 inflammasome activation in liver diseases, discusses its contribution to hepatic inflammation and fibrosis, and explores emerging therapeutic strategies targeting this pathway. Understanding NLRP3-mediated immune regulation may provide new opportunities for precision-based treatments in chronic liver disease.

Keywords: NLRP3 inflammasome; liver disease; MASLD; MASH; fibrosis; pyroptosis; IL-1β; targeted therapy

Introduction

Chronic liver diseases represent a major global health challenge and contribute substantially to morbidity and mortality worldwide. Conditions including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease, viral hepatitis, liver fibrosis, and hepatocellular carcinoma involve complex interactions between metabolic stress, immune activation, inflammation, and tissue remodeling. Although therapeutic advances have improved outcomes in several liver disorders, effective treatments specifically targeting chronic inflammation and fibrosis remain limited. Increasing evidence has identified inflammasome activation as a critical component of hepatic immune regulation and disease progression, with the NLRP3 inflammasome emerging as a key mediator of liver inflammation and injury.[1]

The NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome is an intracellular multiprotein signaling complex involved in innate immune responses. It detects a wide range of cellular danger signals, including reactive oxygen species, mitochondrial dysfunction, extracellular ATP, and pathogen-associated molecular patterns. Activation of the NLRP3 inflammasome requires assembly of the NLRP3 sensor, the adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC), and caspase-1. Following activation, caspase-1 promotes the maturation of pro-inflammatory cytokines such as interleukin (IL)-1β and IL-18 and induces gasdermin D-mediated pyroptosis, resulting in amplification of inflammatory responses.[2]

In the liver, NLRP3 inflammasome activation occurs in multiple cell types, including Kupffer cells, hepatocytes, and hepatic stellate cells. Physiological activation of this pathway contributes to host defense and tissue repair; however, excessive or persistent activation promotes chronic inflammation, hepatocyte injury, and fibrosis. Dysregulated NLRP3 signaling has been implicated in several chronic liver diseases by enhancing inflammatory cytokine production, oxidative stress, immune cell recruitment, and profibrotic signaling pathways.[3]

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most prevalent chronic liver disease worldwide, driven by increasing rates of obesity, diabetes, and metabolic syndrome. Progression from simple hepatic steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma involves multiple mechanisms, including lipotoxicity, mitochondrial dysfunction, and immune activation. NLRP3 inflammasome activation represents an important link between metabolic stress and hepatic inflammation. Recent studies have demonstrated that NLRP3 signaling contributes to hepatocyte injury, macrophage activation, insulin resistance, and hepatic stellate cell-mediated fibrosis in metabolic liver disease.[4]

Experimental studies have provided direct evidence supporting the pathogenic role of NLRP3 in liver injury. Wree et al. demonstrated that NLRP3 inflammasome activation caused hepatocyte pyroptosis, hepatic inflammation, and fibrosis in animal models, establishing NLRP3 as a major regulator of inflammatory liver damage. These findings highlighted the importance of inflammasome-mediated cell death and cytokine signaling in the progression of chronic liver disease.[5]

Further evidence has shown that inhibition of NLRP3 can attenuate liver inflammation and fibrosis. Mridha et al. demonstrated that pharmacological blockade of the NLRP3 inflammasome reduced inflammatory responses and fibrotic changes in experimental models of nonalcoholic steatohepatitis, suggesting that targeting this pathway may provide therapeutic benefit in metabolic liver disease.[6]

The therapeutic potential of NLRP3 inhibition has stimulated the development of selective inflammasome-targeting agents. Coll et al. identified MCC950, a small-molecule inhibitor that selectively blocks NLRP3 inflammasome activation and reduces inflammatory cytokine production. Although promising in experimental studies, translation of NLRP3 inhibitors into clinical practice requires further evaluation regarding safety, efficacy, and appropriate patient selection.[7]

Recent investigations have expanded understanding of NLRP3 activation in metabolic dysfunction-associated fatty liver disease and explored potential therapeutic strategies targeting inflammasome pathways. These approaches include direct NLRP3 inhibition, modulation of upstream inflammatory pathways, and metabolic interventions that indirectly reduce inflammasome activation.[8]

Beyond metabolic liver disease, NLRP3 signaling has been increasingly recognized as an important regulator of broader inflammatory processes. Chronic activation of the inflammasome may contribute to tumor-promoting inflammation, immune dysregulation, and progression of malignant liver disease. Understanding the balance between protective and harmful NLRP3 activation remains essential for developing targeted therapies.[9]

Given the central role of inflammation in liver disease progression, integrating knowledge of NLRP3 signaling with current concepts of hepatic metabolism and immune regulation may provide new opportunities for precision medicine approaches. This review discusses the molecular mechanisms of NLRP3 inflammasome activation, its contribution to different liver diseases, and emerging therapeutic strategies targeting this pathway.[10]

Discussion

Biology and Molecular Mechanisms of the NLRP3 Inflammasome

The NLRP3 inflammasome is a key component of the innate immune system that regulates inflammatory responses following cellular stress and tissue injury. Unlike immune sensors that recognize specific pathogens, NLRP3 responds to a broad range of danger signals, including oxidative stress, mitochondrial dysfunction, extracellular ATP, lipid accumulation, and pathogen-associated molecular patterns. This ability to detect diverse stress signals makes NLRP3 an important mediator of sterile inflammation and a major contributor to chronic inflammatory diseases, including liver disorders.[1]

Structure and Components of the NLRP3 Inflammasome

The NLRP3 inflammasome is a multiprotein complex consisting of three major components: the NLRP3 sensor protein, the adaptor molecule apoptosis-associated speck-like protein containing a CARD (ASC), and caspase-1. NLRP3 functions as the intracellular sensor that detects cellular stress signals and undergoes conformational activation. ASC acts as a bridging protein that connects NLRP3 with pro-caspase-1, allowing formation of the inflammasome complex.

Following inflammasome assembly, caspase-1 becomes activated and cleaves inactive precursor cytokines, including pro-interleukin (IL)-1β and pro-IL-18, into their active inflammatory forms. These cytokines promote immune cell recruitment, inflammatory signaling, and amplification of tissue injury.[1,2]

Activation Pathway of the NLRP3 Inflammasome

NLRP3 activation occurs through a two-step process involving priming and activation signals.

Priming Phase

The first step involves activation of inflammatory transcription pathways, particularly nuclear factor kappa B (NF-κB). Various stimuli, including Toll-like receptor activation, inflammatory cytokines, and

microbial products, increase transcription of NLRP3 and pro-inflammatory cytokine precursors such as pro-IL-1β and pro-IL-18.

In chronic liver disease, persistent metabolic stress and inflammatory signaling provide continuous priming signals that increase susceptibility to NLRP3 activation.[1,3]

Activation Phase

The second step involves assembly of the NLRP3 inflammasome in response to cellular stress signals. Important activators include:

- Reactive oxygen species generation
- Mitochondrial dysfunction
- Extracellular ATP release
- Potassium efflux
- Lysosomal injury
- Cholesterol crystal accumulation

These signals trigger NLRP3 oligomerization, ASC recruitment, and caspase-1 activation, resulting in increased production of IL-1β and IL-18. Persistent activation of this pathway contributes to chronic inflammation and progressive tissue damage in liver disease.[2,3]

NLRP3 Inflammasome and Pyroptosis

A major downstream effect of NLRP3 activation is pyroptosis, an inflammatory form of programmed cell death. Activated caspase-1 cleaves gasdermin D, resulting in pore formation in the cell membrane and release of inflammatory mediators.

In the liver, pyroptosis contributes to hepatocyte injury and inflammatory amplification. Damaged hepatocytes release danger signals that activate surrounding immune cells, creating a cycle of inflammation and tissue damage. This mechanism has been particularly implicated in metabolic liver disease, where lipotoxicity and oxidative stress promote hepatocyte injury and inflammasome activation.[1,4]

Cellular Sources of NLRP3 Activation in the Liver

Multiple hepatic cell types participate in NLRP3-mediated inflammation.

Kupffer Cells

Kupffer cells are resident macrophages of the liver and represent an important source of NLRP3-driven inflammatory cytokines. Activation of these cells results in increased IL-1β and IL-18 production, recruitment of inflammatory immune cells, and promotion of hepatic inflammation.[3]

Hepatocytes

Hepatocytes activate NLRP3 signaling in response to metabolic stress, including lipid accumulation, mitochondrial dysfunction, and oxidative injury. In metabolic liver disease, damaged hepatocytes contribute to inflammatory signaling by releasing danger-associated molecular patterns that activate immune pathways.[4]

Hepatic Stellate Cells

Hepatic stellate cells are central mediators of fibrosis. Inflammatory cytokines released during NLRP3 activation promote stellate cell activation, extracellular matrix deposition, and collagen production. Therefore, NLRP3 signaling serves as an important connection between inflammation and fibrotic progression in chronic liver disease.[5,6]

Overall, the NLRP3 inflammasome functions as a central regulatory pathway linking cellular stress, innate immune activation, hepatocyte injury, and fibrosis. Understanding these molecular mechanisms provides

the foundation for evaluating NLRP3 as a therapeutic target in liver disease.

Role of the NLRP3 Inflammasome in Liver Diseases

The liver is continuously exposed to metabolic stress, microbial products, and inflammatory stimuli, requiring tightly regulated immune responses to maintain tissue homeostasis. However, persistent activation of innate immune pathways can result in chronic inflammation, hepatocyte injury, and fibrosis. Among these pathways, the NLRP3 inflammasome has emerged as a critical regulator of hepatic inflammation and disease progression. Abnormal activation of NLRP3 signaling has been implicated in several liver disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), liver fibrosis, viral hepatitis, and hepatocellular carcinoma.[1–3]

NLRP3 Inflammasome in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)

MASLD has become the most common chronic liver disease worldwide and is strongly associated with obesity, insulin resistance, type 2 diabetes mellitus, and metabolic syndrome. While simple steatosis may remain stable in many patients, a subset progresses to MASH, characterized by hepatocyte injury, inflammation, and progressive fibrosis. The transition from metabolic stress to inflammatory liver injury involves multiple pathways, with NLRP3 activation playing a central role.[4]

Excessive accumulation of free fatty acids and toxic lipid metabolites causes hepatocyte lipotoxicity, mitochondrial dysfunction, and increased production of reactive oxygen species (ROS). These cellular stress signals activate the NLRP3 inflammasome in hepatocytes and hepatic macrophages, resulting in increased production of IL-1β and IL-18. These inflammatory cytokines promote insulin resistance, recruitment of immune cells, and activation of hepatic stellate cells, contributing to fibrosis progression.[1,4]

Experimental studies have demonstrated a direct relationship between NLRP3 activation and MASH development. Wree et al. showed that activation of the NLRP3 inflammasome resulted in hepatocyte pyroptosis, hepatic inflammation, and fibrosis in animal models, demonstrating its role as a driver of progressive liver injury.[5] Furthermore, inhibition of NLRP3 signaling reduced inflammatory cytokine production and fibrosis in experimental models of MASH, supporting the therapeutic potential of targeting this pathway.[6]

Recent studies have also highlighted the interaction between metabolic dysfunction and inflammasome activation. Factors such as obesity, mitochondrial stress, altered gut microbiota, and increased intestinal permeability may enhance NLRP3 activation and accelerate disease progression. Therefore, NLRP3 represents an important molecular link between metabolic abnormalities and chronic hepatic inflammation.[4,8]

NLRP3 Inflammasome in Alcohol-Associated Liver Disease

Alcohol-associated liver disease represents a spectrum of disorders ranging from hepatic steatosis to alcoholic hepatitis, fibrosis, and cirrhosis. Alcohol metabolism generates acetaldehyde and reactive oxygen species, resulting in oxidative stress, mitochondrial injury, and hepatocyte damage. In addition, chronic alcohol consumption disrupts intestinal barrier integrity, leading to increased translocation of bacterial products such as lipopolysaccharide (LPS) into the portal circulation.[1,3]

LPS activates hepatic immune cells through pattern recognition receptors and promotes inflammatory signaling pathways that enhance NLRP3 inflammasome activation. Activated Kupffer cells release IL-1β and IL-18, leading to inflammatory cell recruitment and amplification of hepatic injury. Persistent activation of this pathway contributes to progression from acute inflammatory injury to chronic fibrosis.[1,3]

The role of NLRP3 in alcohol-associated liver disease highlights the importance of the gut–liver axis and immune-mediated mechanisms in disease progression. Modulation of inflammasome activity may therefore represent a potential therapeutic strategy for reducing alcohol-related hepatic inflammation.[2]

NLRP3 Inflammasome in Liver Fibrosis and Cirrhosis

Liver fibrosis represents a wound-healing response to chronic injury and is characterized by excessive deposition of extracellular matrix proteins. Although fibrosis can initially be reversible, persistent inflammation leads to progressive architectural distortion, cirrhosis, and liver failure.

NLRP3 contributes to fibrosis through multiple mechanisms involving inflammatory cytokine production and activation of hepatic stellate cells. IL-1β released after inflammasome activation promotes inflammatory signaling and stimulates fibrogenic pathways. Activated hepatic stellate cells undergo transformation into collagen-producing myofibroblasts, resulting in extracellular matrix accumulation and fibrosis progression.[3],[5]

Experimental evidence suggests that inhibition of NLRP3 reduces hepatic inflammation and collagen deposition. Studies in animal models have demonstrated that blocking NLRP3 activation decreases fibrosis severity, supporting the concept that inflammasome inhibition may provide antifibrotic effects.[6]

NLRP3 Inflammasome in Viral Hepatitis

Chronic viral hepatitis remains an important cause of liver-related morbidity worldwide. Viral infections stimulate innate immune responses through recognition of pathogen-associated molecular patterns. NLRP3 activation may contribute to antiviral defense by promoting IL-18-mediated immune responses and enhancing natural killer cell activity.

However, persistent activation of inflammasome pathways may become harmful by maintaining chronic inflammation and promoting fibrosis. Excessive IL-1β and IL-18 production can contribute to hepatocyte injury and immune-mediated tissue damage. Therefore, NLRP3 signaling has both protective and pathogenic roles in viral liver disease.[2],[3]

NLRP3 Inflammasome in Hepatocellular Carcinoma

Chronic inflammation is a major contributor to hepatocellular carcinoma development. Persistent activation of inflammatory pathways creates a tumor-promoting microenvironment characterized by oxidative stress, immune dysregulation, and abnormal cellular proliferation.

NLRP3-mediated cytokine release may contribute to tumor progression by promoting chronic inflammation, angiogenesis, and immune escape mechanisms. Although the exact role of NLRP3 in hepatocellular carcinoma remains complex, emerging evidence suggests that modulation of inflammasome activity may influence cancer progression and response to immunotherapeutic approaches.[9],[10]

The evidence across different liver diseases demonstrates that NLRP3 functions as a central connection between cellular stress, inflammation, and fibrosis. Understanding disease-specific patterns of NLRP3 activation may help identify patients who could benefit from targeted inflammasome-based therapies.

Therapeutic Strategies Targeting the NLRP3 Inflammasome in Liver Disease

The central role of the NLRP3 inflammasome in hepatic inflammation, pyroptosis, and fibrosis has generated significant interest in developing therapeutic approaches aimed at modulating this pathway. Current management of chronic liver diseases primarily focuses on controlling metabolic risk factors, eliminating viral infections, or treating complications of advanced disease. However, therapies directly targeting inflammatory mechanisms remain limited. Because NLRP3 acts as a key regulator connecting

cellular stress with inflammatory injury, inhibition of this pathway represents a promising strategy for preventing liver disease progression.[1],[4]

Direct NLRP3 Inflammasome Inhibitors

Direct inhibition of NLRP3 represents one of the most targeted approaches for controlling inflammasome-mediated inflammation. Among available experimental agents, MCC950 is one of the most extensively studied selective NLRP3 inhibitors. MCC950 inhibits NLRP3 activation and prevents downstream caspase-1 activation, resulting in reduced production of IL-1β and IL-18.

In experimental models of inflammatory diseases, MCC950 has demonstrated significant anti-inflammatory effects. Studies investigating liver disease models suggest that inhibition of NLRP3 activation can reduce hepatic inflammation, hepatocyte injury, and fibrosis. The ability of MCC950 to selectively inhibit NLRP3 without broadly suppressing immune function makes it an attractive therapeutic candidate.[7]

However, translation of direct NLRP3 inhibitors into clinical practice remains challenging. Previous clinical development programs have been limited by concerns regarding safety, pharmacokinetics, and potential effects on host immune defense. Further studies are required to determine optimal dosing, long-term safety, and patient populations most likely to benefit from NLRP3-targeted therapy.[4]

Targeting Downstream IL-1β and IL-18 Signaling

Activation of the NLRP3 inflammasome results in production of inflammatory cytokines, particularly IL-1β and IL-18. Therefore, blocking downstream cytokine signaling represents another potential therapeutic approach.

Inhibition of IL-1 signaling has been explored in several inflammatory disorders. Blocking IL-1 activity may reduce hepatic inflammation by decreasing immune cell recruitment and inflammatory amplification. Similarly, modulation of IL-18 signaling may influence immune activation and fibrosis progression.

Although these approaches have shown biological effectiveness in inflammatory conditions, their role in chronic liver disease requires further investigation. Challenges include identifying patients with excessive inflammasome activation and balancing suppression of harmful inflammation while maintaining normal immune function.[1],[2]

Metabolic Therapies and Their Effects on NLRP3 Activation

*Bec*ause metabolic stress is a major driver of NLRP3 activation in MASLD/MASH, therapies that improve metabolic dysfunction may indirectly reduce inflammasome activity.

GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists improve glucose metabolism, promote weight loss, and reduce hepatic steatosis. Their beneficial effects may partly involve reduction of oxidative stress and inflammatory signaling pathways, including NLRP3 activation. These agents represent an important therapeutic avenue for patients with metabolic liver disease.[4],[8]

SGLT2 Inhibitors

Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve metabolic parameters and cardiovascular outcomes in patients with diabetes. Emerging evidence suggests that these agents may reduce oxidative stress and inflammatory signaling, potentially influencing NLRP3 activation. Further clinical studies are needed to define their specific role in MASLD/MASH management.[8]

Lifestyle-Based Modulation of NLRP3 Activity

Lifestyle interventions remain fundamental in the management of metabolic liver disease and may influence inflammasome activity.

Weight Reduction

Weight loss improves insulin sensitivity, reduces hepatic fat accumulation, and decreases inflammatory signaling. Reduction of metabolic stress may lead to decreased activation of NLRP3 pathways.

Exercise

Regular physical activity improves mitochondrial function, reduces oxidative stress, and may decrease inflammatory activation within hepatic tissues.

Dietary Modification

Dietary approaches that reduce saturated fat intake and improve metabolic health may decrease triggers responsible for NLRP3 activation, including lipid accumulation and oxidative stress.[4],[10]

Combination Therapeutic Approaches

Given the complex nature of chronic liver disease, targeting NLRP3 alone may not be sufficient. Future strategies may involve combination approaches integrating inflammasome inhibition with metabolic therapies, antifibrotic agents, and lifestyle interventions.

For example, combining NLRP3 inhibitors with therapies targeting obesity, insulin resistance, or fibrosis pathways may provide synergistic benefits by addressing both the initiating metabolic abnormalities and downstream inflammatory consequences.[4],[6]

Challenges and Future Directions

Despite promising experimental findings, several challenges remain before NLRP3-targeted therapies can become part of routine clinical practice.

Major limitations include:

- Lack of large-scale human clinical trials in liver disease
- Potential risk of impaired host immune defense
- Difficulty identifying patients with clinically significant NLRP3 activation
- Need for reliable biomarkers to monitor inflammasome activity

Future research should focus on developing selective NLRP3 inhibitors, identifying predictive biomarkers, and determining which liver disease populations are most likely to benefit from inflammasome-directed therapies. Integration of molecular profiling with clinical characteristics may enable personalized therapeutic approaches targeting inflammatory pathways.[4],[9]

Overall, targeting the NLRP3 inflammasome represents a promising strategy for addressing the inflammatory component of chronic liver disease. Continued investigation is required to translate experimental success into effective and safe clinical therapies.

Biomarkers, Clinical Translation, and Future Perspectives

The growing recognition of the NLRP3 inflammasome as a central regulator of hepatic inflammation has created opportunities for developing biomarkers and personalized therapeutic approaches in chronic liver disease. Although experimental studies have demonstrated a strong association between NLRP3 activation and liver injury, fibrosis, and disease progression, translating these findings into clinical practice remains challenging. Identifying reliable biomarkers of inflammasome activation and determining patient populations most likely to benefit from targeted therapies will be essential for successful clinical implementation.[1],[4]

Potential Biomarkers of NLRP3 Inflammasome Activation

Currently, there are no validated clinical biomarkers specifically approved for measuring NLRP3 inflam-

masome activity in patients with liver disease. However, several inflammatory mediators and molecular markers have shown potential utility.

Interleukin-1β and Interleukin-18

IL-1β and IL-18 are the primary cytokines generated following NLRP3 activation. Increased levels of these cytokines have been associated with inflammatory liver conditions and may reflect enhanced inflammasome activity. However, their lack of specificity limits their use as standalone biomarkers.[1,2]

Caspase-1 Activation and Pyroptosis Markers

Because caspase-1 activation is a key step in inflammasome signaling, measurement of caspase-1 activity may provide insight into NLRP3 activation. In addition, markers associated with pyroptosis, including gasdermin D cleavage products, may help identify ongoing inflammatory cell death and tissue injury.[2]

NLRP3 Expression and Inflammasome-Related Gene Signatures

Assessment of NLRP3 expression in liver tissue or immune cells may provide information regarding inflammasome activation. Future approaches combining transcriptomic analysis, proteomics, and clinical parameters may enable more accurate identification of patients with inflammasome-driven disease.[4,9]

Challenges in Clinical Translation

Although targeting NLRP3 has shown promising results in experimental liver disease models, several challenges must be addressed before clinical application.

Limited Human Clinical Evidence

Most available evidence supporting NLRP3 inhibition comes from cellular and animal studies. Although these models have provided important mechanistic insights, differences between experimental models and human disease progression remain a major limitation. Large-scale clinical trials are required to evaluate the efficacy and safety of NLRP3-directed therapies in patients with liver disease.[4]

Balancing Inflammation and Host Defense

Inflammasomes are essential components of innate immunity and contribute to protective responses against infections. Complete suppression of NLRP3 activity may impair immune defense and increase susceptibility to infection. Therefore, future therapies will likely require selective modulation rather than complete inhibition of inflammasome function.[1,2]

Patient Selection and Precision Medicine

Chronic liver diseases are biologically heterogeneous, and not all patients exhibit the same degree of inflammasome activation. Identifying individuals with significant NLRP3-driven inflammation will be important for maximizing therapeutic benefit. Integration of biomarkers, metabolic characteristics, and molecular profiling may allow development of personalized treatment strategies.[4,9]

Future Therapeutic Directions

Future research is likely to focus on improving the specificity and clinical applicability of NLRP3-targeted therapies.

Development of Next-Generation NLRP3 Inhibitors

Newer inhibitors with improved safety profiles, oral availability, and tissue specificity may overcome limitations associated with earlier compounds. Selective inhibition of excessive inflammasome activation while preserving normal immune function represents an important therapeutic goal.[7]

Combination Therapy Approaches

Because liver disease involves multiple interacting pathways, combination therapies may provide greater benefit than targeting a single mechanism. Potential combinations include:

- NLRP3 inhibitors with metabolic therapies

- Inflammasome modulation with antifibrotic agents
- NLRP3 targeting combined with lifestyle interventions

Such approaches may simultaneously address metabolic injury, inflammation, and fibrosis progression.[4,6]

Role in Hepatocellular Carcinoma and Immunotherapy

The relationship between NLRP3 activation and cancer immunity represents an emerging area of research. Because chronic inflammation contributes to tumor development, modulation of inflammasome signaling may influence hepatocellular carcinoma progression and response to immune-based therapies. Further investigation is needed to clarify whether NLRP3 inhibition may provide therapeutic advantages in liver cancer.[9,10]

Future Perspectives

The NLRP3 inflammasome represents an important connection between metabolic dysfunction, immune activation, and fibrosis in liver disease. Advances in molecular biology have expanded understanding of how inflammasome signaling contributes to disease progression and have identified new opportunities for therapeutic intervention.

Future studies should focus on:

- Development of clinically validated biomarkers of NLRP3 activation
- Long-term safety evaluation of inflammasome inhibitors
- Identification of patient populations most likely to respond
- Integration of NLRP3-targeted therapies with existing metabolic and antifibrotic treatments

As understanding of immune-mediated mechanisms in liver disease continues to evolve, NLRP3-directed therapies may become an important component of precision medicine strategies for chronic liver disorders.[1,4]

Conclusion

The NLRP3 inflammasome is a key regulator of hepatic inflammation, immune activation, and fibrosis, playing a critical role in the pathogenesis of metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, viral hepatitis, liver fibrosis, and hepatocellular carcinoma. By linking cellular stress to inflammatory signaling, it drives disease progression and represents a promising therapeutic target. Emerging strategies targeting the NLRP3 pathway have shown encouraging preclinical results, although further clinical studies are needed to establish their safety, efficacy, and long-term benefits. Continued research into NLRP3-mediated mechanisms and biomarker development will be essential for translating these advances into precision therapies that improve outcomes for patients with chronic liver diseases.

Acknowledgement

The authors sincerely express their gratitude to their respective institutions for providing an academic environment and access to resources that supported the preparation of this review. We also acknowledge the contributions of researchers and clinicians worldwide whose pioneering work on the NLRP3 inflammasome, liver diseases, and emerging therapeutic strategies has laid the foundation for this manuscript. Their dedication to advancing scientific knowledge has been invaluable in shaping our understanding of the molecular mechanisms and clinical implications of inflammasome-mediated liver injury.

The authors are grateful to their colleagues, mentors, and peers for their encouragement, constructive discussions, and continuous support throughout the development of this manuscript. Finally, we extend our appreciation to our families for their unwavering patience, understanding, and encouragement during the course of this work.

References

1. Ribeiro MC, Szabo G. Role of the Inflammasome in Liver Disease. *Annu Rev Pathol.* 2022;17:345-365.
2. Sayaf K, Battistella S, Russo FP. NLRP3 Inflammasome in Acute and Chronic Liver Diseases. *Int J Mol Sci.* 2024;25(8):4537.
3. Wu X, Dong L, Lin X, Li J. Relevance of the NLRP3 Inflammasome in the Pathogenesis of Chronic Liver Disease. *Front Immunol.* 2017;8:1728.
4. Ma W, Wang Y, Liu J. NLRP3 Inflammasome Activation in Liver Disorders: From Molecular Pathways to Therapeutic Strategies. *J Inflamm Res.* 2025;18:8277-8294.
5. Wree A, Eguchi A, McGeough MD, et al. NLRP3 Inflammasome Activation Results in Hepatocyte Pyroptosis, Liver Inflammation, and Fibrosis in Mice. *Hepatology.* 2014;59(3):898-910.
6. Mridha AR, Wree A, Robertson AAB, et al. NLRP3 Inflammasome Blockade Reduces Liver Inflammation and Fibrosis in Experimental NASH in Mice. *J Hepatol.* 2017;66(5):1037-1046.
7. Coll RC, Robertson AAB, Chae JJ, et al. A Small-Molecule Inhibitor of the NLRP3 Inflammasome for the Treatment of Inflammatory Diseases. *Nat Med.* 2015;21:248-255.
8. Zhang X, Xu A, Li Y, et al. NLRP3 Inflammasome Activation in Metabolic Dysfunction-Associated Fatty Liver Disease. *Front Pharmacol.* 2022.
9. NLRP3 Inflammasome in Health and Disease. PMCID: PMC11781521.
10. Loomba R, Friedman SL, Shulman GI. Mechanisms and Disease Consequences of Nonalcoholic Fatty Liver Disease. *Cell.* 2021;184(10):2537-2564.